Shire's Ornskov Maps Out Future Prospects Post- Baxalta Merger
Executive Summary
Shire's Danish chief executive says completing the Baxalta merger will greatly boost the group's exposure to longer acting orphan drugs, bring critical mass and de-risk its current asset mix with new portfolio products; a view widely shared by investors and analysts.
You may also be interested in...
Shire's Ornskov On Goals And Accomplishments One Year After Baxalta Merger
Shire's CEO says he sees scientific and technological advances as an opportunity to become the leading rare disease company. Ornskov also talked about the firm's debt-reduction and M&A strategy going forward.
Shire's Record Year Bolstered By Baxalta, But Shows Across-The-Board Growth
Baxalta's hemophilia franchise immediately becomes Shire's top seller, but the specialty firm enjoyed sales growth across its business areas. Meanwhile, the launch of Xiidra is off to an impressive start in market share and patient access.
2Q Pharma Results Preview: Pfizer, Shire, Merck KGaA, Teva, Novo Nordisk And Allergan
Pfizer, Merck KGaA, Novo Nordisk, Shire, Allergan and Teva are among those pharmaceutical majors still to report their 2Q results. Scrip considers what’s in store.